SARATOGA, Calif., May 1 /PRNewswire/ -- VisionCare Ophthalmic
Technologies, Inc., a developer of advanced visual prosthetic devices for
the treatment of age-related macular degeneration (AMD), announced today
two presentations on its platform technology are scheduled at the upcoming
Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 6 - 10, 2007, in Fort Lauderdale, Florida. VisionCare has filed a
Premarket Approval (PMA) application amendment for the telescope prosthesis
seeking marketing approval for the treatment of central vision loss due to
advanced, irreversible forms of AMD.
Presentations are scheduled at the Greater Fort Lauderdale/Broward
County Convention Center as follows:
Monday, May 7, 8:30AM - 10:15AM
Long-Term Visual Results and Post-Operative Patient Management Factors of
a Telescope Prosthesis for End-Stage AMD
S.A. Primo, R.D. Stulting, IMT002 Study Group. Emory University Eye
Center, Atlanta, GA.
Session Number/Title: 215, Visual Function and Quality of Life I
Location: Hall B/C
Wednesday, May 9, 3:00PM - 3:15PM
Evaluation of End-Stage AMD Implantable Telescope Eyes With Retinal and
Anterior Segment OCT
H.L. Hudson, IMT002 Study Group. Retina Centers PC, Tucson, AZ.
Session Number/Title: 464, Retinal Prosthesis
Location: Grand Floridian B
About the Telescope Prosthetic Device
The investigational Implantable Miniature Telescope (IMT(TM) by Dr.
Isaac Lipshitz) is designed to be a permanent solution for moderate to
profound vision loss due to advanced, end-stage forms of AMD that have no
current surgical or medical treatment options. Smaller than a pea, the
telescope prosthetic device is implanted in one eye in an outpatient
surgical procedure. In the implanted eye, the device renders enlarged
central vision images over a wide area of the retina to improve central
vision, while the non-operated eye provides peripheral vision for mobility
The prospective, multicenter IMT002 Phase II/III trial was designed to
evaluate the safety and efficacy of VisionCare's investigational medical
device in individuals with moderate to profound bilateral central vision
impairment associated with end-stage AMD. The trial enrolled over 200
patients at 28 leading medical universities and ophthalmic centers across
the country. VisionCare has filed a Premarket Approval (PMA) application
amendment for the telescope prosthesis. The submission seeks marketing
approval for the treatment of central vision loss due to advanced,
irreversible forms of AMD. To date, no additional clinical investigations
have been requested. Assuming no significant additional analyses or
clinical data are required, the Company projects regulatory approval in the
second half of 2007.
About Macular Degeneration
Macular degeneration is a disorder of the central retina, or macula,
which is responsible for detailed vision that controls important functional
visual activities like reading, recognizing faces, and watching television.
According to the National Eye Institute over 1.7 million Americans over age
50 suffer mild to profound vision loss from advanced AMD, which frequently
culminates as end-stage AMD (visual impairment due to untreatable advanced
AMD). Patients affected in both eyes often experience a loss of
independence, social interaction, and have difficulty with activities of
daily living requiring detailed vision. Approximately half of the
individuals living with advanced AMD are affected in both eyes.
VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA
is a privately-held company focused on development, manufacturing, and
marketing of visual prosthetic devices. The Implantable Miniature Telescope
was invented by company founders, Isaac Lipshitz, M.D., and Yossi Gross.
Information on VisionCare can be found at http://www.visioncareinc.net.
SOURCE VisionCare Ophthalmic Technologies, Inc.